134 related articles for article (PubMed ID: 36566799)
1. Design of Crotoxin-Based Peptides with Potentiator Activity Targeting the ΔF508NBD1 Cystic Fibrosis Transmembrane Conductance Regulator.
Ravatin M; Odolczyk N; Servel N; Guijarro JI; Tagat E; Chevalier B; Baatallah N; Corringer PJ; Lukács GL; Edelman A; Zielenkiewicz P; Chambard JM; Hinzpeter A; Faure G
J Mol Biol; 2023 Feb; 435(3):167929. PubMed ID: 36566799
[TBL] [Abstract][Full Text] [Related]
2. Rattlesnake Phospholipase A2 Increases CFTR-Chloride Channel Current and Corrects ∆F508CFTR Dysfunction: Impact in Cystic Fibrosis.
Faure G; Bakouh N; Lourdel S; Odolczyk N; Premchandar A; Servel N; Hatton A; Ostrowski MK; Xu H; Saul FA; Moquereau C; Bitam S; Pranke I; Planelles G; Teulon J; Herrmann H; Roldan A; Zielenkiewicz P; Dadlez M; Lukacs GL; Sermet-Gaudelus I; Ollero M; Corringer PJ; Edelman A
J Mol Biol; 2016 Jul; 428(14):2898-915. PubMed ID: 27241308
[TBL] [Abstract][Full Text] [Related]
3. Crystal Structure of Isoform CBd of the Basic Phospholipase A
Nemecz D; Ostrowski M; Ravatin M; Saul F; Faure G
Molecules; 2020 Nov; 25(22):. PubMed ID: 33202772
[TBL] [Abstract][Full Text] [Related]
4. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
[TBL] [Abstract][Full Text] [Related]
5. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
6. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
[TBL] [Abstract][Full Text] [Related]
7. Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides.
Ferrera L; Cappiello F; Loffredo MR; Puglisi E; Casciaro B; Botta B; Galietta LJV; Mori M; Mangoni ML
Cell Mol Life Sci; 2021 Dec; 79(1):67. PubMed ID: 34971429
[TBL] [Abstract][Full Text] [Related]
8. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
9. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.
Phuan PW; Yang B; Knapp JM; Wood AB; Lukacs GL; Kurth MJ; Verkman AS
Mol Pharmacol; 2011 Oct; 80(4):683-93. PubMed ID: 21730204
[TBL] [Abstract][Full Text] [Related]
10. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
Yu W; Kim Chiaw P; Bear CE
J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
[TBL] [Abstract][Full Text] [Related]
11. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
Lin WY; Sohma Y; Hwang TC
Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
[TBL] [Abstract][Full Text] [Related]
13. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
[TBL] [Abstract][Full Text] [Related]
14. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
15. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
[TBL] [Abstract][Full Text] [Related]
16. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
18. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.
Caputo A; Hinzpeter A; Caci E; Pedemonte N; Arous N; Di Duca M; Zegarra-Moran O; Fanen P; Galietta LJ
J Pharmacol Exp Ther; 2009 Sep; 330(3):783-91. PubMed ID: 19491324
[TBL] [Abstract][Full Text] [Related]
19. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
[TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
